August 27, 2016 1:20 PM ET

Healthcare Providers and Services

Company Overview of St. Jude Children's Research Hospital, Inc.

Company Overview

St. Jude Children's Research Hospital, Inc. operates a pediatric treatment and research facility. It also engages in the research and treatment of blood disorders, cancer, and infectious diseases in children. St. Jude Children's Research Hospital, Inc. was formerly known as St Jude Children's Research Hospital, Memphis, Tennessee. The company was founded in 1959 and is based in Memphis, Tennessee.

262 Danny Thomas Place

Memphis, TN 38105

United States

Founded in 1959

Phone:

901-595-3300

Fax:

901-595-3966

Key Executives for St. Jude Children's Research Hospital, Inc.

Chief Executive Officer and President
Chief Financial Officer
Chief Legal Officer and Senior Vice President
Chief Communications Officer and Senior Vice President
Chief Nursing Officer and Senior Vice President of Patient Care Services
Compensation as of Fiscal Year 2016.

St. Jude Children's Research Hospital, Inc. Key Developments

St. Jude Children's Research Hospital Appoints James Morgan as Scientific Director and Executive Vice President

St. Jude Children's Research Hospital has named James Morgan, Ph.D., scientific director and executive vice president. Morgan held the interim scientific director post since 2015, and was formerly chair of the Department of Developmental Neurobiology. As scientific director, Morgan will oversee the institution's basic science programs and related research efforts. The appointment comes as St. Jude takes steps to strengthen its basic research programs to advance the fight against childhood cancer and other life-threatening diseases.

St Jude Children's Research Hospital Names Michael Dyer as Chair of the Department of Developmental Neurobiology

St Jude Children's Research Hospital named Michael Dyer, Ph.D., chair of the Department of Developmental Neurobiology. Dyer, who joined St. Jude in 2002 as an assistant member in Developmental Neurobiology, has received numerous awards for his work. Dyer's current research is focused on understanding how retinal progenitor cells coordinate proliferation and cell fate specification during development, and how genetic alterations in solid tumors, particularly retinoblastoma, can provide leads for the development of new therapeutic approaches.

NanoViricides Signs Agreement with St. Jude Children's Research Hospital for Further Influenza Drug Development

NanoViricides, Inc. announced that it has entered into an agreement with St. Jude Children's Research Hospital for further drug development in its anti-influenza program. NanoViricides, Inc. has previously held a pre-IND meeting with the US FDA on its anti-influenza drug development program, and obtained valuable guidance. Since then, the Company has been performing necessary CMC (chemistry, manufacture, and control) studies and production scale-up for the identified development candidate, namely, FluCide™-I. The Company has also continued further anti-influenza drug development that is anticipated to result in additional candidates superior to FluCide-I. The testing of these candidates for anti-influenza activity will be performed in the laboratory of Dr. Elena Govorkova in collaboration with Dr. Robert G. Webster and will include both in vitro and in vivo studies. They have extensive experience in influenza virus infections with a large number of different influenza strains, and in anti-viral agents discovery. The overall objective of these studies will be to help select clinical drug development candidates for the treatment of influenza virus in humans, using both the injectable and oral administration routes. Injectable administration is preferable for hospitalized patients that are extremely sick, while oral administration is preferred for out-patients. The in vitro studies will evaluate the efficacy and potency of the Company's nanoviricides anti-viral agents against a panel of influenza A and B virus infection of different types of cells, including human bronchial epithelial cells. The in vivo studies in small animals will evaluate the safety and efficacy of the Company's nanoviricides to protect against severe H1N1 influenza infection.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1125 Sir Francis Drake Boulevard Operating Company, Llc United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact St. Jude Childrens Research Hospital, Inc., please visit www.stjude.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.